🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Longtime biotech VC Jack Nielsen passes away. Also in BioCentury's management moves column: Ambrx alum Jared Kelly named CEO of Oncolytics, Courtney Cupples to lead commercial for Abcuro buff.ly/KblLb39

A new way of thinking about academia-industry collaboration — a special #BioCenturyGrandRounds edition of the #BioCenturyThisWeek podcast featuring Simone Fishburn 🎗️ & Josh Berlin, top BioCentury analysts and special guests buff.ly/VC9BUzN

Splicebio's $135M series B, the largest round ever for a Spain-based biotech, is the latest sign of a maturing ecosystem in that country buff.ly/RNPb5ZS

French neurology start-up Elkedonia unveils new CEO, seed round headlines BioCentury's latest management roundup. Plus: New CEOs for Elekta, Aicure, Slingshot and more buff.ly/6CvJjDQ

Korea biotech’s playbook for success: Orum’s SJ Lee in conversation with Executive Editor @Jeff_Cranmer on The #BioCenturyShow buff.ly/tGIb3Tg

Insmed’s hypertension readout spurs $750M follow-on. Also in BioCentury's Public Equity Report are financings for Enliven, Cabaletta, Keymed and ADC Therapeutics; a planned IPO for Caris; and Odyssey’s withdrawn listing buff.ly/a2RMRtT

Can U.S. science funding cuts spark collaboration? BioCentury's Danielle Golovin argues in a Perspective that the proposed slashing of the NIH budget may force more cross-sector communication: a silver lining that could bring long-term benefits. buff.ly/OCl97Lq

On heels of Metsera, Lilly delivers more momentum for amylin in obesity $LLY #ADA2025 buff.ly/yn5MAO6

Sarepta’s latest tragedy—the second death of a DMD patient treated with its gene therapy—calls for FDA leadership, industry collaboration on AAV liver toxicity: An Editors' Commentary buff.ly/f1rU1gT

AZ in $5.3 discovery deal with China-based CSPC; Biontech acquiring fellow mRNA co Curevac; Supernus buying Sage; and more: in BioCentury Deals Report buff.ly/aj3I9aM

Head of Roche Venture Nuechterlein to depart. Plus: Illumina Ventures’ Willis now CEO of Arima, Goldman’s Shibutani to head strategy for BMS, and more buff.ly/1cMiGTJ

Computational health sciences pioneer Atul Butte passes buff.ly/T9OXf4Q

A $1B bet on gene editing could bolster Lilly’s CV arsenal buff.ly/xVlX3qC

BioCentury's biopharma management moves: Broader role for Prasad at U.S. FDA. Plus: Alnylam promotes Garg; new CMOs for Tolremo, Climb Bio buff.ly/cOZ5chz

Intellia bolsters case for CRISPR-Cas9 durability and safety. Plus: an updated norovirus vaccine from Vaxart, early CML results from Enliven, and more, in BioCentury’s Clinical Report buff.ly/vnkQGnY

Industry, patients excited and concerned about U.S. FDA pilot commissioner's priority review voucher program. Washington Editor @SteveUsdin1 explains buff.ly/VEDfXCA

Former Amarin CEO Karim Mikhail has joined FDA as a senior advisory to Commissioner Makary and is a candidate to serve as CDER Director buff.ly/xYHFIuf

Five positive opinions for new drugs at June CHMP meeting: a BioCentury Data Byte buff.ly/YX10IG7

Caris lands largest NASDAQ IPO in two years. Plus: Venture rounds for Welsh start-up Draig, San Diego’s Actio, in BioCentury's Finance Report buff.ly/wBGMzNa

.@IamBIO broke the mold when it named Genentech SVP Fritz Bittenbender board chair. Read BioCentury's Q&A: MFN, Biosecure, IRA and more. buff.ly/nht29QX